

Synagis

Prior Authorization Criteria

The dose of palivizumab (Synagis) is 15 mg/kg . RSV prophylaxis should be given monthly, as appropriate, starting at the beginning of the RSV season and stopping at the end of the season. The RSV season is November 1 through March 31.*

Infants with Chronic Lung Disease (CLD) or Congenital Heart Disease (CHD)

- I. Infants younger than 2 years of age with CLD who have required medical therapy (such as oxygen, bronchodilator, diuretic or corticosteroid therapy for their CLD within six months before the anticipated RSV season
- II. Infants with CHD that is “hemodynamically significant”--on cardiac medication or oxygen, being treated by a pediatric cardiologist or having cardiac surgery planned this year

Premature Infants without CLD

- I. Premature ≤ 28 weeks if born ≤ 12 months before the start of the RSV season
- II. Premature 29-32 weeks if born ≤ 6 months before the start of the RSV season
- III. ***Premature 32 weeks, 0 days to-34 weeks, 6 days if born ≤ 3 months before the start of the RSV season and the infant must also have 1 of 2 risk factors present:***

Child care attendance or siblings < 5 years of age

Treatment will be approved for premature infants 32 weeks, 0 days to 34 weeks, 6 days until the infant is 3 months (90 days) of age. A maximum of 3 doses will be approved for this age group.

Treatment will be approved for infants with CLD or CHD throughout the RSV season

Treatment will be approved for premature infants ≤ 32 weeks throughout the RSV season

American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. *Red Book: 2009 Report of the Committee on Infectious Diseases*. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009: 560-569

** <http://www.cdc.gov/surveillance/nrevss/rsv/state.html> National Respiratory and Enteric Virus Surveillance System-Centers for Disease Control

August 3, 2009 v1.0

Approved 9/16/09 DUR Board